TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Clinical trials for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to cut heart deaths in rare heart condition
Disease control Recruiting nowThis study tests a new medicine, NNC6019-0001, to see if it can lower the risk of heart-related death and hospital stays in people with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition where abnormal proteins build up in the heart. About 1,280 adults with ATTR-CM will …
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New heart drug under the microscope: how does acoramidis perform in real life?
Knowledge-focused Recruiting nowThis study is observing up to 2,000 adults across Europe who are starting a new medication called acoramidis for a serious heart condition (ATTR-CM). The goal is to see how the drug works in everyday medical practice, not in a strict trial setting. Researchers will track patient …
Matched conditions: TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM)
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 11, 2026 20:50 UTC